The first patient has been dosed in a second phase 3 clinical trial of Zimura for the treatment of geographic atrophy secondary to age-related macular degeneration, according to an Iveric bio press release.
Zimura (avacincaptad pegol), a novel complement C5 inhibitor, reached its primary efficacy endpoint in GATHER1, the first phase 3 trial.
In GATHER2, about 400 patients will be randomly assigned to receive monthly administration of either Zimura 2 mg or sham for 12 months. A primary efficacy analysis of the mean rate of change of geographic atrophy growth (Read more...)
Uncategorized